Foundry Healthcare NetDebtFin Factor ETF
ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Hypothetical growth of $1 — long-short backtest
Gross of the placeholder expense ratio and trading costs · not investor results
Holdings
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1UNH | UNITEDHEALTH GROUP INC | Healthcare | $386.95B | 25.59% |
2GILD | GILEAD SCIENCES INC | Healthcare | $166.72B | 11.03% |
3BMY | BRISTOL MYERS SQUIBB CO | Healthcare | $124.04B | 8.20% |
4SYK | STRYKER CORP | Healthcare | $122.63B | 8.11% |
5MDT | MEDTRONIC PLC | Healthcare | $106.50B | 7.04% |
6BSX | BOSTON SCIENTIFIC CORP | Healthcare | $65.44B | 4.33% |
7BDX | BECTON DICKINSON & CO | Healthcare | $43.58B | 2.88% |
8TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Healthcare | $37.30B | 2.47% |
9A | AGILENT TECHNOLOGIES INC | Healthcare | $37.13B | 2.46% |
10WAT | WATERS CORP | Healthcare | $36.23B | 2.40% |
11ALNY | ALNYLAM PHARMACEUTICALS INC | Healthcare | $35.71B | 2.36% |
12CNC | CENTENE CORP | Healthcare | $32.81B | 2.17% |
13DXCM | DEXCOM INC | Healthcare | $29.58B | 1.96% |
14DGX | QUEST DIAGNOSTICS INC | Healthcare | $23.32B | 1.54% |
15UTHR | UNITED THERAPEUTICS CORP | Healthcare | $22.74B | 1.50% |
16STE | STERIS PLC | Healthcare | $21.26B | 1.41% |
17SOLV | SOLVENTUM CORP | Healthcare | $14.08B | 0.93% |
18COO | COOPER COMPANIES INC | Healthcare | $13.99B | 0.92% |
19BTSG | BRIGHTSPRING HEALTH SERVICES INC | Healthcare | $13.71B | 0.91% |
20ELAN | ELANCO ANIMAL HEALTH INC | Healthcare | $12.90B | 0.85% |
21AXSM | AXSOME THERAPEUTICS INC | Healthcare | $11.84B | 0.78% |
22BAX | BAXTER INTERNATIONAL INC | Healthcare | $11.68B | 0.77% |
23PODD | INSULET CORP | Healthcare | $11.36B | 0.75% |
24TECH | BIO-TECHNE CORP | Healthcare | $11.29B | 0.75% |
25BRKR | BRUKER CORP | Healthcare | $8.86B | 0.59% |
26HQY | HEALTHEQUITY INC | Healthcare | $8.17B | 0.54% |
27PACS | PACS GROUP INC | Healthcare | $7.30B | 0.48% |
28TVTX | TRAVERE THERAPEUTICS INC | Healthcare | $5.27B | 0.35% |
29SHC | SOTERA HEALTH CO | Healthcare | $5.06B | 0.33% |
30LIVN | LIVANOVA PLC | Healthcare | $4.43B | 0.29% |
31CON | CONCENTRA GROUP HOLDINGS PARENT INC | Healthcare | $4.04B | 0.27% |
32ICUI | ICU MEDICAL INC | Healthcare | $3.94B | 0.26% |
33NHC | NATIONAL HEALTHCARE CORP | Healthcare | $3.56B | 0.24% |
34OGN | ORGANON & CO | Healthcare | $3.55B | 0.23% |
35XRAY | DENTSPLY SIRONA INC | Healthcare | $2.81B | 0.19% |
36GRDN | GUARDIAN PHARMACY SERVICES INC | Healthcare | $2.57B | 0.17% |
37NEOG | NEOGEN CORP | Healthcare | $2.24B | 0.15% |
38MD | PEDIATRIX MEDICAL GROUP INC | Healthcare | $2.15B | 0.14% |
39HTFL | HEARTFLOW INC | Healthcare | $2.15B | 0.14% |
40ADUS | ADDUS HOMECARE CORP | Healthcare | $2.14B | 0.14% |
41AXGN | AXOGEN INC | Healthcare | $2.12B | 0.14% |
42OMCL | OMNICELL INC | Healthcare | $2.09B | 0.14% |
43AUPH | AURINIA PHARMACEUTICALS INC | Healthcare | $2.05B | 0.14% |
44HRMY | HARMONY BIOSCIENCES HOLDINGS INC | Healthcare | $1.96B | 0.13% |
45NEO | NEOGENOMICS INC | Healthcare | $1.90B | 0.13% |
46UFPT | UFP TECHNOLOGIES INC | Healthcare | $1.87B | 0.12% |
47MRVI | MARAVAI LIFESCIENCES HOLDINGS INC | Healthcare | $1.87B | 0.12% |
48NVCR | NOVOCURE LTD | Healthcare | $1.84B | 0.12% |
49SRPT | SAREPTA THERAPEUTICS INC | Healthcare | $1.82B | 0.12% |
50TDOC | TELADOC HEALTH INC | Healthcare | $1.70B | 0.11% |
51ANAB | ANAPTYSBIO INC | Healthcare | $1.69B | 0.11% |
52FTRE | FORTREA HOLDINGS INC | Healthcare | $1.68B | 0.11% |
53PSNL | PERSONALIS INC | Healthcare | $1.61B | 0.11% |
54INNV | INNOVAGE HOLDING CORP | Healthcare | $1.56B | 0.10% |
55AHCO | ADAPTHEALTH CORP | Healthcare | $1.49B | 0.10% |
56BLFS | BIOLIFE SOLUTIONS INC | Healthcare | $1.42B | 0.09% |
57OMDA | OMADA HEALTH INC | Healthcare | $1.41B | 0.09% |
58AMN | AMN HEALTHCARE SERVICES INC | Healthcare | $1.36B | 0.09% |
59CNMD | CONMED CORP | Healthcare | $1.30B | 0.09% |
60ABSI | ABSCI CORP | Healthcare | $1.29B | 0.09% |
61COLL | COLLEGIUM PHARMACEUTICAL INC | Healthcare | $1.17B | 0.08% |
62NUTX | NUTEX HEALTH INC | Healthcare | $1.12B | 0.07% |
63BIOA | BIOAGE LABS INC | Healthcare | $1.01B | 0.07% |
64PCRX | PACIRA BIOSCIENCES INC | Healthcare | $1.01B | 0.07% |
65BVS | BIOVENTUS INC | Healthcare | $1.01B | 0.07% |
66ANNX | ANNEXON INC | Healthcare | $950M | 0.06% |
67PHAT | PHATHOM PHARMACEUTICALS INC | Healthcare | $873M | 0.06% |
68ZVRA | ZEVRA THERAPEUTICS INC | Healthcare | $755M | 0.05% |
69RIGL | RIGEL PHARMACEUTICALS INC | Healthcare | $750M | 0.05% |
70OMER | OMEROS CORP | Healthcare | $701M | 0.05% |
71EVH | EVOLENT HEALTH INC | Healthcare | $654M | 0.04% |
72TCMD | TACTILE SYSTEMS TECHNOLOGY INC | Healthcare | $648M | 0.04% |
73WEAV | WEAVE COMMUNICATIONS INC | Healthcare | $575M | 0.04% |
74NPCE | NEUROPACE INC | Healthcare | $548M | 0.04% |
75XOMA | XOMA ROYALTY CORP | Healthcare | $504M | 0.03% |
76VREX | VAREX IMAGING CORP | Healthcare | $444M | 0.03% |
77PBYI | PUMA BIOTECHNOLOGY INC | Healthcare | $434M | 0.03% |
78ENTA | ENANTA PHARMACEUTICALS INC | Healthcare | $400M | 0.03% |
79ABEO | ABEONA THERAPEUTICS INC | Healthcare | $399M | 0.03% |
80EBS | EMERGENT BIOSOLUTIONS INC | Healthcare | $394M | 0.03% |
81TBRG | TRUBRIDGE INC | Healthcare | $394M | 0.03% |
82FENC | FENNEC PHARMACEUTICALS INC | Healthcare | $365M | 0.02% |
83QTTB | Q32 BIO INC | Healthcare | $255M | 0.02% |
84SMTI | SANARA MEDTECH INC | Healthcare | $229M | 0.02% |
85AGEN | AGENUS INC | Healthcare | $209M | 0.01% |
86PDEX | PRO DEX INC | Healthcare | $183M | 0.01% |
87INFU | INFUSYSTEM HOLDINGS INC | Healthcare | $180M | 0.01% |
88ARCT | ARCTURUS THERAPEUTICS HOLDINGS INC | Healthcare | $172M | 0.01% |
89CUE | CUE BIOPHARMA INC | Healthcare | $126M | 0.01% |
90OPRX | OPTIMIZERX CORP | Healthcare | $126M | 0.01% |
91ICCC | IMMUCELL CORP | Healthcare | $101M | 0.01% |
92NRXS | NEURAXIS INC | Healthcare | $84M | 0.01% |
93FRMM | FORUM MARKETS INC | Healthcare | $83M | 0.01% |
94SNWV | SANUWAVE HEALTH INC | Healthcare | $55M | 0.00% |
95INKT | MINK THERAPEUTICS INC | Healthcare | $53M | 0.00% |
Full long-leg book as of July 2026 · cap-weighted · total market cap $1.51T. Hypothetical model holdings — not a registered fund’s portfolio.
Sector Breakdown
Portfolio Style
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 98% toward Large, 50% toward Growth. +4% unclassified (15 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → July 2026; the right-hand end is the same value as the box’s dot. 95 names now. The faded start covers early months with a much thinner universe. Hypothetical holdings — descriptive, not P&L.
Constraint checks
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.
Required>= 75.0%Actual65.0%Margin-10.0%No more than 25% of total assets may be invested in the securities of any one issuer.
Required<= 25.0%Actual25.6%Margin-0.6%Close to the line. The engine flags this verdict as one a routine data rebuild could flip. Read it as borderline rather than settled — the margin beside it is the whole story.
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
1 verdict(s) sit within 1.0pp of their limit and can be flipped by a routine data rebuild; do not headline them, and always show the margin.
Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700
Measured on the 2026-07 formation date across 95 holdings (cap-weighted). A different formation date can produce different verdicts.
Derivatives risk (Rule 18f-4)
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months
The estimators agree, which is mild evidence the number isn’t an artefact of one method.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Since publication
Did the edge survive the paper coming out?
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Consistency across eras
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Returns
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 14.7% | -22.9% |
| 3 yearsp.a. | 4.0% | -12.7% |
| 5 yearsp.a. | 0.9% | -9.4% |
| 10 yearsp.a. | 8.1% | -4.0% |
| Since inceptionp.a. | 10.3% | 0.3% |
| Year | Long leg | Long-short |
|---|---|---|
| 20267 mo | -3.7% | -15.3% |
| 2025 | 13.5% | -11.1% |
| 2024 | 3.7% | -5.8% |
| 2023 | -7.7% | -18.4% |
| 2022 | -7.4% | -3.1% |
| 2021 | 35.3% | 25.1% |
| 2020 | 12.6% | -6.5% |
| 2019 | 21.6% | -6.2% |
| 2018 | 12.0% | 14.8% |
| 2017 | 21.4% | 1.7% |
| 2016 | -9.7% | -3.1% |
| 2015 | 14.0% | 7.8% |
| 2014 | 18.8% | -11.7% |
| 2013 | 43.1% | -3.8% |
| 2012 | 19.6% | -5.2% |
| 2011 | 14.1% | 12.5% |
| 2010 | 14.0% | 10.5% |
| 2009 | 21.2% | 6.3% |
| 2008 | -28.4% | -14.2% |
| 2007 | 8.9% | 8.5% |
| 2006 | 14.1% | 15.5% |
| 2005 | 5.6% | -13.0% |
| 2004 | 2.3% | -0.5% |
| 2003 | 48.9% | 31.5% |
| 2002 | -21.5% | 0.7% |
| 2001 | 4.3% | 23.9% |
| 2000 | 33.9% | -30.8% |
| 1999 | 19.6% | 29.8% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
Fund Facts
Methodology
The Foundry Healthcare NetDebtFin Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a NetDebtFin signal and holds the top quintile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Documents (draft — hypothetical)
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.